8-K: BioCryst's ORLADEYO Receives FDA Priority Review for Pediatric HAE Treatment

BioCryst Pharmaceuticals announces FDA acceptance and priority review for ORLADEYO in pediatric HAE patients, with a PDUFA target action date of September 12, 2025.

Summary

• BioCryst Pharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for ORLADEYO (berotralstat) oral granules for pediatric patients aged 2 to 11 years with hereditary angioedema (HAE).
• The FDA granted priority review, setting a Prescription Drug User Fee Act (PDUFA) target action date of September 12, 2025.
• BioCryst has also filed a line extension application with the European Medicines Agency for the same indication.
• Additional regulatory filings are planned in other global territories, including Japan and Canada.
• The NDA is based on positive interim data from the APeX-P clinical trial, which showed ORLADEYO was well-tolerated and resulted in early and sustained reductions in monthly attack rates.

Sentiment

Score: 8

Explanation: The document presents positive news regarding regulatory progress for ORLADEYO, supported by clinical trial data. While forward-looking statements include standard risk disclosures, the overall tone is optimistic.

Positives

• FDA acceptance of the NDA and granting of priority review indicate a potentially faster path to approval for ORLADEYO in pediatric HAE patients.
• Positive interim data from the APeX-P clinical trial supports the safety and efficacy of ORLADEYO in this age group.
• If approved, ORLADEYO would be the first targeted oral prophylactic therapy for HAE in patients under 12, addressing an unmet need.
• The company is expanding regulatory filings to other global territories, including Europe, Japan, and Canada, increasing the potential market for ORLADEYO.

Negatives

• The FDA, European Medicines Agency or other applicable regulatory agency may not approve ORLADEYO for use in pediatric patients with HAE aged 2 to 11 years within the timeframe expected, or at all.
• The commercial viability of ORLADEYO for use in pediatric patients with HAE aged 2 to 11 years, including its ability to achieve sustained market acceptance, is uncertain.

Risks

• The FDA may require additional information or studies, disagree with the company's safety and efficacy conclusions, or impose restrictions, warnings, or other requirements.
• Ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
• The company's ability to successfully implement or maintain its commercialization plans for ORLADEYO is subject to risks and uncertainties.

Future Outlook

BioCryst anticipates potential approval and commercialization of ORLADEYO for pediatric HAE patients, as well as expansion into other global territories.

Management Comments

• Jon Stonehouse, president and chief executive officer of BioCryst, stated that they are excited to take another step closer to bringing ORLADEYO to younger pediatric patients with HAE.
• Dr. Helen Thackray, chief research and development officer of BioCryst, believes that the oral granule formulation of ORLADEYO could help children with HAE and their families better manage their condition and avoid the traumatic experience of acute attacks.

Industry Context

The announcement addresses the need for convenient therapeutic options for young children with HAE, a market segment with limited treatment options. The approval of ORLADEYO could give BioCryst a competitive advantage in the HAE market.

Comparison to Industry Standards

• ORLADEYO competes with other HAE prophylactic treatments such as Takhzyro (lanadelumab) from Takeda and Haegarda (C1 esterase inhibitor subcutaneous) from CSL Behring.
• Unlike these injectable treatments, ORLADEYO offers an oral administration route, potentially improving patient convenience and adherence.
• The APeX-P trial results will be compared to data from trials of other HAE therapies in pediatric populations to assess relative efficacy and safety.

Stakeholder Impact

• Positive impact on pediatric HAE patients and their families by providing a potential new oral treatment option.
• Potential benefit to BioCryst shareholders through increased revenue and market share if ORLADEYO is approved.
• Positive impact on physicians by providing an additional treatment option for their pediatric HAE patients.

Next Steps

• The FDA will review the NDA with a PDUFA target action date of September 12, 2025.
• BioCryst will continue to pursue regulatory filings in other global territories, including Japan and Canada.
• The company will continue to monitor and analyze data from the APeX-P clinical trial.

Key Dates

Keywords

ORLADEYO, berotralstat, HAE, hereditary angioedema, FDA, priority review, pediatric, BioCryst, APeX-P, NDA